FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 1AD | $0.01 | 0.00% | $0.01 | $0.00 |
|
||
| ACR | $0.01 | 0.00% | $0.02 | $0.01 |
|
||
| ACW | $0.04 | 0.00% | $0.07 | $0.02 |
|
||
| ADO | $0.02 | 0.00% | $0.05 | $0.01 |
|
||
| AFP | $3.29 |
|
$3.37 | $2.20 |
|
||
| AGN | $0.16 |
|
$0.77 | $0.09 |
|
||
| ARX | $0.56 | 0.00% | $0.80 | $0.50 | 37.4 |
$0.94 |
|
| ATH | $0.56 |
|
$0.79 | $0.01 |
|
||
| AVH | $1.43 |
|
$1.98 | $1.00 |
$1.275 |
|
|
| BIO | $0.26 | 0.00% | $0.62 | $0.20 | 23.6 |
$0.75 |
|
| BOT | $0.02 | 0.00% | $0.18 | $0.02 |
|
||
| COV | $0.36 |
|
$0.90 | $0.34 |
|
||
| CSL | $117.94 |
|
$275.79 | $90.00 | 12.7 |
$130.584 |
|
| CUV | $9.88 |
|
$14.00 | $8.35 | 14.0 |
$15.00 |
|
| DXB | $0.25 |
|
$0.67 | $0.16 |
|
||
| GSS | $0.06 | 0.00% | $0.43 | $0.06 |
$0.10 |
|
|
| IDT | $0.03 |
|
$0.10 | $0.03 |
|
||
| ILA | $0.42 | 0.00% | $0.63 | $0.14 |
|
||
| IMM | $0.05 | 0.00% | $0.47 | $0.03 |
$0.07 |
|
|
| IMU | $0.09 | 0.00% | $0.46 | $0.09 |
$0.25 |
|
|
| IVX | $0.04 | 0.00% | $0.20 | $0.03 |
|
||
| LGP | $0.08 | 0.00% | $0.15 | $0.06 |
|
||
| MAP | $0.05 | 0.00% | $0.11 | $0.04 |
$0.085 |
|
|
| MSB | $2.34 |
|
$3.31 | $1.88 | -30.5 |
$4.45 |
|
| MVP | $0.38 |
|
$0.77 | $0.37 |
$0.85 |
|
|
| MYX | $2.77 |
|
$6.50 | $2.04 |
|
||
| NEU | $17.29 |
|
$22.99 | $11.00 | 44.2 |
$24.367 |
|
| NUZ | $0.06 | 0.00% | $0.19 | $0.06 |
$0.20 |
|
|
| OCC | $0.72 |
|
$1.60 | $0.70 |
$1.19 |
|
|
| OPT | $0.01 | 0.00% | $0.60 | $0.01 |
|
||
| OSL | $1.15 |
|
$2.09 | $0.37 |
|
||
| PAR | $0.18 |
|
$0.47 | $0.14 |
$0.45 |
|
|
| PER | $0.01 | 0.00% | $0.01 | $0.00 |
|
||
| PNV | $0.95 | 0.00% | $1.67 | $0.87 | 98.3 |
$1.703 |
|
| PYC | $1.61 |
|
$1.76 | $0.85 |
$2.30 |
|
|
| RAC | $2.05 |
|
$4.90 | $1.14 |
|
||
| RCE | $0.35 |
|
$0.73 | $0.35 |
|
||
| SNT | $0.02 | 0.00% | $0.07 | $0.02 |
$0.06 |
|
|
| SPL | $0.70 | 0.00% | $0.79 | $0.09 |
|
||
| TLX | $14.86 |
|
$21.96 | $8.26 | 255.0 |
$26.225 |
|
| TRP | $0.10 |
|
$0.48 | $0.10 |
|
||
| VIT | $0.03 | 0.00% | $0.08 | $0.02 |
|
||
| ZNO | $0.06 | 0.00% | $0.18 | $0.03 |
|
3.13% Previous Stories
Dr Boreham’s Crucible: Radiopharm Theranostics
Jul 03 2024
The New Criterion’s Tim Boreham explains the how and why behind Radiopharm Theranostics’ latest capital raising
Dr Boreham’s Crucible: Island Therapeutics
Jun 17 2024
The next twelve months could be exciting for Dengue fever solutions seeker Island Therapeutics, the New Criterion’s Tim Boreham reports
Dr Boreham’s Crucible: Amplia Therapeutics
Jun 05 2024
Amplia Therapeutics is in pursuit of a cancer drug for pancreatic cancer and possibly other indications including ovarian cancer, the New Criterion’s Tim Boreham reports
Is The Long Wait For CSL About To End?
May 30 2024
The Chartist reports it looks like CSL shares might be ready to leave the past four-year pause in the past
Dr Boreham’s Crucible: Invion
May 13 2024
As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission
Dr Boreham’s Crucible: Race Oncology
Apr 09 2024
Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports
The Power Of New Weight-Loss Drugs
Apr 03 2024
GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price’s Nabil Hanano
Dr Boreham’s Crucible: Neuren Pharmaceuticals
Mar 11 2024
Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked
Spotlight On ASX-Listed Cannabis Companies
Jan 31 2024
Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports
Transformational Trial Results For Neuren Pharmaceuticals
Dec 20 2023
Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results
Latest News
| 1 |
ASX Winners And Losers Of Today – 22-07-266:35 PM - Daily Market Reports |
| 2 |
Strong Result, Can Telix Continue To Deliver?3:36 PM - Australia |
| 3 |
AI’s Show Me The Money Moment11:00 AM - Australia |
| 4 |
Technical Views On Nasdaq, ASX200 & Oil10:30 AM - Technicals |
| 5 |
Australian Broker Call *Extra* Edition – Jul 22, 202610:30 AM - Daily Market Reports |